Health
FDA Grants Early Accelerated Approval for GSK’s Nelkarmi in Advanced ALK-Positive Lung Cancer
The U.S. Food and Drug Administration has granted early accelerated approval to GSK’s kinase inhibitor, Nelkarmi (neladalkib), for adults with previously treated, locally advanced or metastatic…